Key clinical point: Investigators found no difference between laquinimod and placebo on motor function in Huntington’s disease.
Major finding: The study examined 0.5-mg, 1.0-mg, and 1.5-mg doses of laquinimod.
Study details: The phase 2 LEGATO-HD trial included 352 patients with Huntington’s disease who underwent a 52-week treatment period.
Disclosures: Dr. Reilmann has received research support from Teva, which supported the LEGATO-HD trial and in 2018, sold development and commercial rights for laquinimod to Active Biotech. He has received research support from a variety of other pharmaceutical companies and organizations, including the CHDI Foundation and the European Huntington Disease Network.
Reilmann R et al. AAN 2019, Abstract S16.007.
This Week's Must Reads
Must Reads in Neuromuscular Disorders
Global Burden of Motor Neuron Diseases Examined, Lancet Neurol; ePub 2018 Nov 5; Logroscino, et al
FDA Approves Tiglutik for Treatment of ALS, ITF Pharma news release; 2018 Sep 6